Pharmaceutical cocrystals of an analgesic drug ethenzamide (ETZ) with various coformers, namely, gallic acid (GA), 2-nitrobenzoic acid (2NB), 3-nitrobenzoic acid (3NB), 2,4-dinitrobenzoic acid (DNB), and 3-toluic acid (3TA) were synthesized by the solvent evaporation method. All the cocrystals were characterized by various analytical techniques, and the crystal structures were determined by the single-crystal X-ray diffraction method (SCXRD). SCXRD analysis revealed that all the synthesized cocrystals were formed through a robust supramolecular acid-amide heterosynthon except the ethenzamide/gallic acid cocrystal, where molecules interacted through O−H•••O hydrogen bond involving −OH of gallic acid and oxygen of amide group of the ETZ molecule. The physicochemical properties such as stability, hygroscopicity, and solubility studies of the ETZ−GA cocrystal were evaluated. It was found that the ETZ−GA cocrystal has a higher solubility (2fold) than that of the pure ETZ drug molecule. Hygroscopic study of the ETZ−GA cocrystal revealed that synthesized cocrystal was non-hygroscopic at ∼75% RH conditions. The ETZ−GA cocrystal found to be stable for a time period of four months at ambient temperature.

No abstract

No abstract

Tranexamic acid (TXA) is an important and essential medicine needed in a health system and is approved by the US FDA for the treatment of excessive blood loss from trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation. One of the notable disadvantages of the TXA drug is that has low absorption (∼35−40%) in the gastrointestinal tract, possibly due to its amphoteric nature. In the present work, nine molecular salts and two cocrystals of the TXA molecule have been synthesized by a simple water-mediated solvent evaporation method. The coformers/counterions used were salicylic acid (SAL), 3-hydroxybenzoic acid (3HBA), 2,4dihydroxybenzoic acid (2,4HBA), 2,5-dihydroxybenzoic acid (2,5HBA), 2,6-dihydroxybenzoic acid (2,6HBA), gallic acid (GAA), oxalic acid (TXA), tartaric acid (TTA), fumaric acid (FUM), succinic acid (SUA), and crotonic acid (CRA). The synthesized salts/cocrystals were characterized by various spectroscopic, thermal, and XRD techniques. The crystal structures of all of the molecular adducts were determined by SC-XRD techniques. In the synthesized salts, charge-assisted acid•••amine heterosynthons and O−H•••O hydrogen bonds between the acid group of TXA and the coformer are favored, and the salts TXA-FUM and TXA-SUA were found to be isostructural on the basis of the isostructural parameters π and ε. In the cocrystal, molecules interacted through the acid group of the coformer with the carboxyl group of the TXA molecule. Further, these salts/ cocrystals were found to be stable for a period of 6 months under ambient conditions (∼25−30 °C, ∼60−65% RH). Furthermore, density functional theory (DFT) calculations were carried out to better understand the geometric structure of the molecules presented in our study. The interaction energies of the molecular salts and cocrystals were calculated, and they supported the reported structure of the crystalline adducts. The cocrystal formation in the case of TXA-GAA and TXA-CRA has been confirmed by a DFT calculation study, as the salt formation in these cases resulted in a higher interaction energy in comparison to the cocrystal. Consequently, these molecular salts offer promise for the development of new drug products of TXA, and a few salts, namely TXA-SAL and TXA-2,5HBA, offer the possibility of development of combination drugs.

No abstract